Physician profile
Claude U Osula
NPI 1235137688
$11,043.17
in general payments reported to CMS, 2019-2025
43 companies · $1,586 in 2025
The $1,586 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,345 · 2020: $1,583 · 2021: $1,593 · 2022: $1,398 · 2023: $1,263 · 2024: $1,275 · 2025: $1,586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,123.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,260.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,428.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $651.42 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $640.63 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $610.89 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $591.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $463.62 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $446.55 | 2019-2025 | |
| Allergan, INC. | $446.35 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $442.61 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $407.05 | 2019-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $390.30 | 2021-2025 | |
| Astellas Pharma US INC | $328.98 | 2019-2023 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $261.05 | 2019-2022 | |
| Corcept Therapeutics | $235.24 | 2019-2025 | Korlym |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Osula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.